Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT06857942
- Locations
- 🇺🇸
NorCal Clinical Research, Rocklin, California, United States
🇺🇸Integrative Skin Science and Research - Location 3, Sacramento, California, United States
🇺🇸Medical Dermatology Specialists, Phoenix, Arizona, United States
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 586
- Registration Number
- NCT06859268
- Locations
- 🇺🇸
Southern California Clinical Research, Santa Ana, California, United States
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸CMR of Greater New Haven, LLC, Hamden, Connecticut, United States
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight
- Conditions
- ObesityOverweight
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT06824051
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Axis, Dilworth, Minnesota, United States
🇺🇸Ohio Clinical Trials, Columbus, Ohio, United States
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT06817356
- Locations
- 🇺🇸
Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸Headlands Research - Scottsdale, Scottsdale, Arizona, United States
🇺🇸Woodland Resarch Northwest/ERG, Rogers, Arkansas, United States
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 127
- Registration Number
- NCT06809400
- Locations
- 🇺🇸
Collaborative Neuroscience Network - CNS, Los Alamitos, California, United States
🇺🇸PPD Development, LP, Austin, Texas, United States
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT06808802
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 55
- Registration Number
- NCT06739122
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸Arkansas Childrens Hospital, Little Rock, Arkansas, United States
🇺🇸Division of Endocrinology, Diabetes, and Metabolism, Los Angeles, California, United States
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
- Conditions
- Immune Thrombocytopenia (ITP)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 58
- Registration Number
- NCT06721013
- Locations
- 🇺🇸
Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸MedStar Georgetown University Hospital, Washington, District of Columbia, United States
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT06719128
- Locations
- 🇺🇸
Orange County Research Center, Lake Forest, California, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study of LY4060874 in Healthy Participants
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 132
- Registration Number
- NCT06709820
- Locations
- 🇺🇸
Fortrea, Inc., Dallas, Texas, United States
🇸🇬Lilly Centre for Clinical Pharmacology, Singapore, Singapore